No Prescription |
 |
 | ||
|
Janumet Generic Metformin |
|
| ||
No Prescription » Prescription Drugs 9 » Janumet Generic Metformin Janumet is an oral diabetes medicines that help control blood sugar levels.Metformin works by decreasing glucose (sugar) production in the liver and decreasing absorption of glucose by the intestines.Sitagliptin works by regulating the levels of insulin your body produces after eating.Janumet is for people with type 2 diabetes who do not use daily insulin injections. It is used along with diet and exercise. Janumet is not for treating type 1 diabetes. Buy Janumet Generic Metformin and other Prescription Drugs 9 products online at Medstore. Buy Online at Medstore - Click Here!
About Janumet Generic Metformin: Product Type: Prescription Drugs 9 Janumet (Generic Metformin/Sitagliptin) Janumet (Generic Metformin/Sitagliptin) Generic Metformin/Sitagliptin 1000/50mg 14 Tablets 3 x 14 Tablets 6 x 14 Tablets Generic Metformin/Sitagliptin Janumet
View more Prescription Drugs 9 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
